• Arrivent Biopharma Inc AVBP.OQ reported a quarterly adjusted loss of 90 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -65 cents. The mean expectation of eight analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -80 cents to -52 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Arrivent Biopharma Inc's reported EPS for the quarter was a loss of 90 cents​.

• The company reported a quarterly loss of $31.4 million.

• Arrivent Biopharma Inc shares had fallen by 22.1% this quarter and lost 36.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.9% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00, about 56.5% above its last closing price of $16.95

This summary was machine generated from LSEG data August 13 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)